Development of Monoclonal Antibodies: The Dawn of mAb Rule.
Development of Monoclonal Antibodies: The Dawn of mAb Rule.
复制标题
单克隆抗体的开发:单克隆抗体规则的黎明。
DOI:
10.1007/s10620-017-4478-1
复制
发表时间:
2017
影响因子:
3.1
通讯作者:
Kaunitz,JonathanD
中科院分区:
文献类型:
--
作者:
Kaunitz,JonathanD
Underlying most major therapeutic advances are fundamental discoveries that shake scientific discourse to its core, usually generating Nobel prizes and entirely new fields of study. In this eighth installment of the series entitled ‘‘Paradigm Shifts in Perspective,’’Drs. Sofia and Rubin highlight the considerable impact that therapeutic monoclonal antibodies (mAbs) have made on gastrointestinal practice.The history of antibody development can be traced back to the eighteenth century, with the discovery that fluid obtained from a smallpox pustule when injected into a recipient provided immunity from acquiring the disease. Edward Jenner, who famously used fluid from cowpox pustules to immunize against smallpox, advanced these studies. The discovery of antibodies can be traced to von Behring and Kitasato, who in 1890 published the landmark finding that transfer of serum from animals that had been immunized to diphtheria to animals infected with diphtheria altered the course of the disease. Going forward to the twentieth century, the pioneering work of Paul Ehrlich and Emil Fischer regarding antibody configuration was remarkably predictive of the current understanding of antibody structure. The Nobel Prize was awarded in 1972 to Gerald Edelman and Rodney Porter for their contributions to the understanding of the chemical structure of antibodies.